Briacell Therapeutics (CVE:BCT) Sets New 52-Week Low at $0.04

Briacell Therapeutics Corp (CVE:BCT)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 219000 shares traded. The stock had previously closed at C$0.04.

The firm’s 50 day moving average is C$0.04 and its two-hundred day moving average is C$0.07. The stock has a market cap of $8.66 million and a price-to-earnings ratio of -1.06. The company has a current ratio of 0.15, a quick ratio of 0.14 and a debt-to-equity ratio of 48.40.

Briacell Therapeutics (CVE:BCT) last released its earnings results on Tuesday, October 22nd. The company reported C($0.03) earnings per share (EPS) for the quarter.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

About Briacell Therapeutics (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co, Inc) for use in patients with breast cancer.

Further Reading: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Leave a Reply

Your email address will not be published. Required fields are marked *